Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 27, 2019

Primary Completion Date

June 26, 2023

Study Completion Date

March 1, 2024

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib

The regimen will be a single oral dose administered daily on a continuous schedule, taken with or without food. The standard dose is 60 mg per day, which can be reduced to 40 or 20 mg according to the latest version of the Summary of Product Characteristics-SPC available. The treating oncologist will evaluate the opportunity to prudentially start treatment at 40 mg/daily in patients screening positively at G8 screening tool, and then escalate to 60 mg/daily only in case of absence of toxicity ³grade 2 at subsequent cycles. Temporary suspensions of treatment are allowed according to the local practice and will be registered if ³ 7 days.

Trial Locations (1)

35100

Istituto Oncologico Veneto, Padua

All Listed Sponsors
lead

Istituto Oncologico Veneto IRCCS

OTHER

NCT04416646 - Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter